- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.12.25 | Tevogen Bio Inc: Tevogen CEO Donates Shares to Support Education for Underprivileged Children | 3 | GlobeNewswire (USA) | ||
| 19.12.25 | Tevogen Bio Inc: Tevogen CEO Donates Personal Shares to Support Local Fire Department | 3 | GlobeNewswire (USA) | ||
| 11.12.25 | Tevogen Bio Inc: Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock | 5 | GlobeNewswire (USA) | ||
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 09.12.25 | Tevogen Bio Inc: Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine | 1 | GlobeNewswire (USA) | ||
| 08.12.25 | Tevogen Bio Inc: Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook | 6 | GlobeNewswire (USA) | ||
| 14.11.25 | Tevogen Bio Inc: Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q | 208 | GlobeNewswire (Europe) | WARREN, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced the filing of its quarterly report on Form 10-Q for the quarter ended... ► Artikel lesen | |
| 14.11.25 | Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11.25 | Tevogen Bio Inc: Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID | 125 | GlobeNewswire (Europe) | This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk... ► Artikel lesen | |
| 03.11.25 | Tevogen Bio Inc: Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn | 129 | GlobeNewswire (Europe) | WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today issued a statement to provide clarity regarding its accumulated deficit reported... ► Artikel lesen | |
| 29.10.25 | Tevogen Bio Inc: Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress | 369 | GlobeNewswire (Europe) | WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to underscore... ► Artikel lesen | |
| 15.10.25 | Tevogen Bio Inc: Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest | 368 | GlobeNewswire (Europe) | Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of... ► Artikel lesen | |
| 26.09.25 | Tevogen Bio Holdings verstößt gegen NASDAQ-Mindestkursanforderung | 4 | Investing.com Deutsch | ||
| 26.09.25 | Tevogen Bio Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.09.25 | Tevogen Bio Inc: Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell-Based Therapies with 100x PredicTcell Beta Data Expansion | 205 | GlobeNewswire (Europe) | Beta version of PredicTcell expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T cell therapies could reliably bind to their target nearly every... ► Artikel lesen | |
| 23.09.25 | Tevogen Bio Inc: Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID | 1 | GlobeNewswire (USA) | ||
| 19.09.25 | Tevogen Bio Inc: Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans | 1 | GlobeNewswire (USA) | ||
| 10.09.25 | Tevogen Bio Inc: Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston | 1 | GlobeNewswire (USA) | ||
| 09.09.25 | Tevogen Bio Inc: Tevogen Estimates 5-Year Top-Line Revenue of ~$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection | 175 | GlobeNewswire (Europe) | Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company")... ► Artikel lesen | |
| 08.09.25 | Tevogen announces $9-11 billion valuation for COVID-19 T cell therapy | 2 | Investing.com | ||
| 08.09.25 | Tevogen Bio Inc: Tevogen Values TVGN-489 at $9-$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell Allogeneic T Cell Platform | 242 | GlobeNewswire (Europe) | WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to... ► Artikel lesen |
1 2 3 4 Weiter >>
76 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,230 | -0,15 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| AMGEN | 278,95 | -1,54 % | Amgen übernimmt Dark Blue für bis zu 840 Millionen Dollar | DJ Amgen übernimmt Dark Blue für bis zu 840 Millionen Dollar
Von Colin Kellaher
DOW JONES--Amgen hat das britische Biotechnologieunternehmen Dark Blue Therapeutics für bis zu 840 Millionen... ► Artikel lesen | |
| NOVAVAX | 6,299 | -0,08 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 16,250 | -5,36 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 680,20 | -1,08 % | Regeneron Just Moved From Underperform To Buy - Here's Why | ||
| INOVIO PHARMACEUTICALS | 1,350 | -2,17 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,540 | -4,35 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 51,78 | 0,00 % | Veeva Systems Expands Long-Term Partnership With BioMarin Pharmaceutical | WASHINGTON (dpa-AFX) - Veeva Systems Inc. (VEEV) and BioMarin Pharmaceutical Inc. (BMRN) on Thursday announced a long-term enterprise agreement that extends their existing relationship.Under... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 55,70 | -0,11 % | Arrowhead Pharmaceuticals prices upsize convertible notes offering to $625M and stock offering at $64.50 | ||
| XOMA ROYALTY | 25,600 | 0,00 % | XOMA Royalty Corporation: XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab | - Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079) -- XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,155 | -2,53 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 | Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| ORAGENICS | 0,823 | -3,13 % | Oragenics Q2 2025 Shareholder Update | Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American:... ► Artikel lesen | |
| LADRX | - | - | LadRx Corp - 8-K, Current Report | ||
| INSMED | 151,00 | +2,72 % | Insmed's 'ginormous' lung drug sales; J&J's US pricing deal |
TEVOGEN BIO HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,019 (+6,05 %) liegt der Kurs bei 0,333 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.